Targeting the KIT activating switch control pocket: A novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation

Leukemia

Volumn 27, Issue 2, 2013, Pages 278-285

  Bai, Y ^a   Bandara, G ^a   Ching Chan, E ^a   Maric, I ^b   Simakova, O ^b   Bandara, S N ^a   Lu, W P ^c   Wise, S C ^c   Flynn, D L ^c   Metcalfe, D D ^a   Gilfillan, A M ^a   Wilson, T M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CLINICAL CENTER   (United States)

^c Deciphera Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DP 2976; DP 4851; PROTEIN KINASE KIT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; DEGRANULATION; DRUG DESIGN; GAIN OF FUNCTION MUTATION; GENE SWITCHING; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOMA; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SYSTEMIC MASTOCYTOSIS;

ANIMALS; CELL PROLIFERATION; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84873571189     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.218     Document Type: Article

References (33)

1. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998; 30: 459-466.
2. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 2008; 154: 1572-1582.
3. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FceR1 mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 2004; 104: 2410-2417.
4. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
5. Horny H-P, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent. P. Mastocytosis. In Swerdlow SH, Campo E, Harris NL, Jaffee ES, Pileri SA, Stein H, Thiele J, Varderman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. (International Agency for Research on Cancer: Lyon, France, 2008; 54-63pp.
6. Verstovsek S, Tefferi A, Cortes J, Brien S, Garcia-Manero G, Pardanani A et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 3906-3915.
7. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintas-Cardama A, Luthra R et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 1481-1484.
8. Andreas H, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP et al. A phase II study of Nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood (ASH Annual Meeting Abstracts) 2006; 108: abstract 2703.
9. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35: 1143-1152.
10. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009; 106: 1542-1547.
11. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J Biol Chem 2004; 279: 31655-31663.
12. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007; 17: 3-7.
13. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
14. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345-355.
15. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(\+), c-kit(\+), and expresses aminopeptidase N (CD13). Blood 1999; 94: 2333-2342.
16. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 1999; 18: 5573-5581.
17. Iwaki S, Spicka J, Tkaczyk C, Jensen BM, Furumoto Y, Charles N et al. Kit-and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal 2008; 20: 195-205.
18. Tkaczyk C, Metcalfe DD, Gilfillan AM. Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J Immunol Methods 2002; 268: 239-243.
19. Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM. Concurrent inhibition of kit-and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 2008; 324: 128-138.
20. Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 2001; 31: 3298-3307.
21. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286-291.
22. Akin C, Brockow K, Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686-692.
23. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752-759.
24. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711-1720.
25. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 2011; 71: 3189-3195.
26. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19: 556-568.
27. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109-1118.
28. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865-2870.
29. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al. KIT Inhibitor Midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: abstract 316.
30. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
31. Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011; 96: 459-463.
32. Sotlar K, Bache A, Stellmacher F, Bultmann B, Valent P, Horny HP. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological nonmast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008; 10: 58-66.
33. Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816Vmutated oncogenic variant of KIT. Haematologica 2007; 92: 1451-1459.